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We have recently described the enzymatic subunit of telomerase (hTERT) as an important prognostic marker for paediatric
ependymoma. Because of the lack of good, representative pre-clinical models for ependymoma, we took advantage of our large
cohort of ependymoma patients, some with multiple recurrences, to investigate telomere biology in these tumours. Our cohort
consisted of 133 ependymomas from 83 paediatric patients and included 31 patients with recurrences. Clinical outcome was
measured as overall survival, progression-free survival and response to therapy. In all 133 tumours, hTERT expression correlated with
proliferative markers, including MIB-1 index (Po0.0001) and mitotic index (P¼0.005), as well as overall tumour grade (P¼0.001),
but not with other markers of anaplasia. There was no correlation between telomere length and hTERT expression or survival.
Surprisingly, prior radiation or chemotherapy neither induced sustained DNA damage nor affected telomere maintenance in
recurrent tumours. There was an inverse correlation between hTERT expression and telomere dysfunction as measured by gH2AX
expression (P¼0.016). Combining gH2AX and hTERT expressions could segregate tumours into three different survival groups
(log rank, Po0.0001) such that those patients whose tumours expressed hTERT and showed no evidence of DNA damage had the
worst outcome. This study emphasises the importance of telomere biology as a prognostic tool and telomerase inhibition as a
therapeutic target for paediatric ependymoma. Furthermore, we have demonstrated that analysing tumours as they progress in vivo is
a viable approach to studying tumour biology in humans.
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Ependymoma is the third most common paediatric brain tumour.
Although there is substantial clinical experience with ependymoma
treatment, tumour behaviour is extremely variable, ranging from
an aggressive course to prolonged survival with multiple relapses
(Bouffet et al, 1998). Although recent attempts at standardising
grading criteria for ependymoma (Tihan et al, 2008) have
improved reproducibility, there is still a large group of tumours
for which assigning a grade is difficult. Furthermore, biological
prognostic factors for this disease have been lacking (Packer, 2005;
Rickert and Paulus, 2005). To address this problem, we recently
reported that the expression of hTERT, the enzymatic subunit of
human telomerase, is the single most important predictor of
outcome among known pathological and clinical risk factors at
diagnosis (Tabori et al, 2006a).
The telomerase complex is integral for telomere maintenance.
Telomeres are unique structures at the ends of chromosomes
whose function is to form ‘caps’ that prevent DNA ends being
recognised as DNA breaks, which would be catastrophic to normal
cells. Telomeres of proliferating cells become shorter until a
critical phase at which they become dysfunctional, resulting in
higher genomic instability or irreversible growth arrest. Telomere
maintenance is one of the hallmarks of cancer and this is believed
to allow their continued proliferation (Hanahan and Weinberg,
2000). Most cancer cells maintain their telomeres by reactivating
hTERT. Others do so by a poorly understood mechanism called
alternative lengthening of telomeres (ALT). Although clearly
telomerase has a critical function in ependymoma behaviour,
currently, there are no data regarding which functions of
telomerase are underlying its association with aggressiveness in
paediatric ependymoma.
Our initial finding of telomerase expression in ependymomas
highlights the need for improved understanding of telomere
biology for the development of better prognostic markers and
new therapies for these devastating tumours. Unfortunately, the
ability to examine functional biological questions in ependy-
momas has been hampered by the lack of available cell lines
and other preclinical models. Therefore, in this study, we took
advantage of our large cohort of ependymoma patients, some
with multiple recurrences, to investigate telomere biology in
these tumours.
Here, we report the biology of telomere maintenance, its
prognostic significance and the effect on response to therapy in
paediatric ependymoma in vivo. Furthermore, the general
methodology described here may be used as an alternative
approach to studying biological processes in tumours where cell
lines are not available.
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Patients
Patients operated on at the Hospital for Sick Children (SickKids,
Toronto, Canada) between 1986 and 2004 with a pathologic
diagnosis of intracranial ependymoma were identified retro-
spectively through the pathology and neuro-oncology databases.
Patients with spinal ependymomas were excluded. In total,
133 tumours from 83 patients were identified and the pathology
reviewed. This included the cohort of our previous study (Tabori
et al, 2006a) with additional patients, and complete data of
recurrence and repeated surgeries/treatments. Formalin-fixed,
paraffin-embedded material was available for all 133 specimens
and was used for tissue microarray construction (see below). For
a subset of 26 of these specimens, matched fresh-frozen material
was available for measuring telomerase enzymatic activity and
telomere length (see below).
Thirty-one patients died of their disease. Fifty-two survivors
were actively observed; of these, 9 patients were lost to follow-up
and, for this analysis, were censored at the time of their last
clinic visit. The study had prior approval from the Research
Ethics Board at SickKids. All data were anonymised prior to
publication.
Clinical data
Clinical data collected included age and metastatic disease
status at presentation, sex, the extent of surgical resection,
chemotherapy use (including protocol and drugs used), radio-
therapy use (including dose and field), progression-free
survival (PFS) and overall survival (OS). For survival analysis
per tumour sampled, progression was the primary end point.
Complete metastatic work-up data, including spinal MRI and
CSF cytology, were available for all patients. The extent of
surgical resection was recorded as gross total resection (GTR) if
no tumour was apparent, as described in the surgical report or
on postoperative magnetic resonance imaging. The latter
imaging technique was used for all patients. Subtotal resection
(STR) was defined as less than 50% residual tumour, and partial
resection (PR) as more than 50% residual tumour. Tumours
that were only biopsied were recorded as such. Total radiation
dose to the tumour bed and craniospinal axis were recorded
separately. Chemotherapy regimens and times were recorded for
initial diagnosis and recurrences. A summary of the clinical data
and tumour hTERT status by resection number is shown in
Table 1.
Morphologic evaluation
A number of histologic features are used to define an ependymoma
as either WHO grade 2 or 3, although no definitive criteria have
been universally accepted. We analysed multiple morphologic
features that have been suggested to indicate tumour grade
including: mitotic index, MIB-1 (Ki67) proliferative index,
hypercellular foci, nuclear pleomorphism, perivascular pseudo-
rosettes, vascular endothelial proliferation and necrosis. Quanti-
fication of the MIB-1 index was measured as the number of
positive cells expressed as a percentage of total tumour cells in the
three high-power fields with greatest positivity (Grotzer et al,
2001). This analysis was carried out using Simple PCI software
(Nikon Canada Inc., Mississauga, ON, Canada). Mitotic index
was counted by two observers blinded to clinical data and
expressed as number per 10 high-power fields. Each of the other
features was evaluated by two observers blinded to clinical data
and recorded as present or absent. For the analysis of grade for this
study, the grade assigned by the original pathologist at the time of
case sign out was used (Tables 1 and 2).
Ependymoma tissue array construction
Tissue arrays were prepared as described earlier by our group
(Ray et al, 2004; Tabori et al, 2006a). Briefly, for each patient,
all pathologic blocks and corresponding slides were obtained
and reviewed by a neuropathologist (CH) for diagnostic accuracy
and tissue adequacy. Representative tumour areas were identified,
and three 1-mm cores were obtained from each tumour, providing
a sampling accuracy of at least 95% (Hoos and Cordon-Cardo,
2001). A variety of tissues, including the liver, ependyma, choroid
plexus, neuroblastoma, and breast cancer, were included around
the periphery of each array to serve as internal controls.
Immunohistochemistry
Sections of 5mm were cut from the tissue microarray and mounted
on positively charged microscope slides. Tissue sections were
then baked overnight at 601C, dewaxed in xylene and hydrated
with distilled water through decreasing concentrations of alcohol.
Immunohistochemistry of hTERT (clone 44F12; Novocastra,
Newcastle upon Tyne, UK) (Yan et al, 2004) and gH2AX (clone
JBW301, Millipore/Upstate, Mississauga, ON, Canada) was per-
formed manually at dilutions of 1:25 and 1:1000, respectively,
Table 1 Clinical features and hTERT status by resection number
N (%)
Characteristic First resection Second resection Third resection
Age 43 years
Yes 46 (61) 22 (55) 8 (67)
No 29 (39) 18 (45) 4 (33)
Sex
Male 41 (55) 21 (53) 4 (33)
Female 34 (45) 19 (47) 8 (67)
Tumour location
Supratentorial 21 (28) 8 (21) 4 (33)
Infratentorial 52 (72) 31 (79) 8 (67)
WHO grade
2 29 (39) 10 (29) 1 (9)
3 46 (61) 25 (71) 10 (91)
Metastatic*
Yes 10 (17) 21 (78) 3 (75)
No 49 (83) 6 (22) 1 (25)
Resection
GTR 32 (43) 14 (37) 2 (18)
Subtotal 38 (52) 20 (53) 9 (82)
Partial 1 (1) 2 (5) 0 (0)
Biopsy 3 (4) 2 (5) 0 (0)
Radiation
Yes   Focal 28 (38) 6 (15) 0 (0)
Yes   Focal+CS 19 (26) 6 (15) 1 (9)
No 26 (36) 28 (70) 11 (91)
Chemotherapy
Yes 38 (53) 17 (57) 6 (50)
No 34 (47) 13 (43) 6 (50)
hTERT
Positive 43 (61) 21 (68) 7 (78)
Negative 28 (39) 10 (32) 2 (22)
*Metastatic disease was defined as either the presence of malignant cells on
cerebrospinal fluid cytology or definite radiographic evidence of spread prior to the
onset of chemo- or radiotherapy.
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Elite avidin–biotin complex method detection system (Vector
Laboratories, Burlingame, CA, USA). MIB-1 (Ki-67 antigen,
DakoCytomation, Dako Canada Inc., Mississauga, ON, Canada),
at a dilution of 1:20, was performed on the Ventana NEXES auto-
immunostainer (Ventana Medical Systems, Tucson, AZ, USA),
with a closed avidin–biotin complex method system using the 3,3-
diaminobenzidine Ventana Detection System. All tissue sections
were treated with heat-induced epitope retrieval and blocked for
endogenous peroxidase and biotin. The counterstain of preference
was haematoxylin. Appropriate positive and negative controls were
also tested in parallel. Conventional sections from paraffin blocks
were used for samples that were of poor quality and for tumours
that were resected after the construction of the tissue array.
Immunohistochemical grading
Immunohistochemical staining for hTERT and gH2AX (nuclear)
was reviewed and graded for both strength (0, none; 1, weak; and 2,
strong) and distribution (o25, 25–50 and 450% of tumour cells)
as described earlier by us (Tabori et al, 2006a). The reviewers were
blinded to clinical patient data at the time of grading. Only
tumours with strong (grade 2) nuclear staining in more than 25%
of tumour cells were considered to be positive for hTERT and
gH2AX expressions. This definition of hTERT positivity correlated
well with telomerase activity in our previous study.
Telomerase activity assay
Tissue of 50mg was homogenised with CHAPS lysis buffer. The
protein concentrations of the samples were determined and equal
quantities used for the assay. Samples were analysed with TRAPeze
kit (Millipore (Canada) Ltd., Etobicoke, Ontario, Canada) reagents
according to the manufacturer’s instructions using 30min of
telomerase extension at 301C, and inactivating telomerase at 851C
for 10min. The extension products were amplified by 35 PCR
cycles (941C for 30s, 561C for 30s and 721C for 60s). A standard
batch of HeLa cells was used as a positive control and lysis buffer
was used as negative control for each run. Polymerase chain
reaction samples (20 AL) were analysed on a 10% non-denaturing
acrylamide gel in 0.5 Tris–borate EDTA at 200V for 4h. Gels were
stained using Syber-Gold and scanned.
Terminal restriction fragment assay
Telomere lengths were determined by a terminal restriction
fragment (TRF) kit (Roche Diagnostics, Mannheim, Germany).
Briefly, extracted DNA samples (1–2mg of tumour DNA) were
digested with the restriction enzymes RsaI and HinfI at 371C for
2h and run on 0.8% agarose gels at 10V for 18h. A biotinylated
g-DNA molecular weight marker was used as DNA length
standard. High- and low-molecular-weight DNAs were run as
positive controls. The DNA samples were depurinated in
0.25moll
 1 of HCl, denatured in 0.4moll
 1 of NaOH/3moll
 1
of NaCl, and transferred to a positively charged nylon membrane
Hybond-N (Amersham Pharmacia Biotech, Little Chalfont, UK) by
capillary blotting over 12h. The membrane was washed in saline–
sodium citrate buffer. The blot was hybridised with a (TTAGGG)
3
telomere probe at 421C for 3h and washed in 2 SSC/0.1%
SDS. Chemiluminescent detection was performed according to the
Detection Kit (Roche Diagnostics, Basel, Switzerland). Detection
was carried out on an X-ray Hyperfilm ECL. To address the issue
of tissue heterogeneity, mean TRF lengths were calculated as
e(ODi)/e(ODi/Li). The final number represents the mean molecular
size of 36 equal to intervals of the telomeric smears in the range of
2–20kb as defined by the DNA length standard. ODi reflects the
measured intensity of luminescence in each of the 35 intervals. As
reported in the literature, TRF lengths were recorded as telomere
lengths.
Telomere fluorescence in situ hybridisation/cH2AX
co-staining
Formalin-fixed, paraffin-embedded sections of 5mm thickness
were dewaxed in xylene followed by rehydration in alcohol series
and allowed to air dry. Antigen retrieval was carried out using a
standard citrate buffer/pressure cooker method for 22min. Slides
were allowed to cool to room temperature, followed by a brief rinse
in water and two washes in 2 SSC for 5min. After dehydration in
alcohol series, cy3-conjugated telomeric PNA probes (Dako,
Mississauga, ON, Canada) was applied and co-denatured at 801C
for 5min followed by hybridisation at room temperature for 1h.
Slides were washed following the manufacturer’s protocol. Slides
were then blocked with donkey serum (1:50) at room temperature
for 3h followed by the addition of monoclonal mouse anti-gH2AX
antibody (1:1000, Upstate Cell Signaling, Temecula, CA, USA) for
an overnight incubation at 41C. Slides were washed four times in
BSA/PBS (0.65gl
 1), followed by the addition of FITC-conjugated
donkey anti-mouse secondary antibody (1:100) for 30min
incubation at room temperature. Slides were washed four times
in BSA/PBS followed by alcohol dehydration. Slides were counter-
stained with DAPI and viewed under a Nikon Eclipse E400
fluorescent microscope with appropriate filters (Nikon Instru-
ments, Toronto, ON, Canada). Digital images were captured with a
Nikon DXM1200F camera and analysed using open source
software ImageJ (http://rsb.info.nih.gov/ij/).
Statistical analysis
For each biological and clinical marker, PFS and OS were
estimated using the Kaplan–Meier method, and significance
testing (a¼0.05) performed on the basis of the log-rank test.
Multivariate analysis was performed using multivariate Cox
proportional hazards models and significance testing (a¼0.05)
performed on the basis of the Wald test. Correlation between
hTERT expression and other parameters was assessed using the
Pearson’s w
2, with Po0.05 considered a significant correlation.
Table 2 Summary of tumour assays done in the study
Criteria
Tumours
analysed
Parameter
measured %
Median
(range)
WHO grade 133 Grade 3 64
Grade 2 36
Proliferative markers
MIB1 109 % Positive 12 (0–69)
Mitoses 94 No. per
10 HPFs
5 (0–76)
Markers of anaplasia
Loss of
pseudorosetting
93 Yes 21
Nuclear atypia 93 Moderate/severe 58
Foci of necrosis 94 Yes 69
Vascular
proliferation
94 Yes 46
Hypercellularity 92 Yes 45
hTERT 113 Positive 62
gH2AX 115 Positive 32
TRF 26 Telomere
length (kb)
6.5 (3.6–9.1)
TRAP 26 Positive 73
Measurements and grading of each assay are detailed in the Materials and Methods
section.
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hTERT expression correlates with proliferative but not
anaplastic markers in ependymomas
We measured multiple markers of proliferation and anaplasia
commonly used in ependymomas (Table 2). We then examined
whether there was a correlation between each of these parameters
and hTERT expression, as well as their ability to predict PFS
(Table 3). Of the morphologic parameters tested, only MIB-1
proliferative index 412% was associated with PFS. hTERT
expression correlated strongly with MIB-1 (Ki67) proliferative
index (Pearson’s w
2 Po0.0001), mitotic index (Pearson’s
w
2 P¼0.005) and tumour grade (Pearson’s w
2 P¼0.001). Grade 2
ependymomas (63%) were hTERT( ) as compared with only 11%
of grade 3 ependymomas (P¼0.002). Interestingly, hTERT
expression did not correlate with other morphologic markers of
tumour anaplasia – marked hypercellularity, nuclear pleomor-
phism, loss of perivascular pseudorosetting, the presence of
necrosis or vascular proliferation. These findings are in keeping
with a specific role for telomerase in allowing continued cellular
proliferation in tumorigenesis.
Telomerase protects telomeres regardless of telomere
length
To determine the correlation between hTERT expression and
telomere status and function in ependymomas, we tested for
telomerase activity, telomere length and DNA damage. The former
two studies were performed on a subset of samples for which
frozen tissue was available (26 samples). The presence of DNA
damage was assessed by the expression of phosphorylated H2AX
(gH2AX), a protein that is rapidly recruited to the sites of DNA
double-stranded breaks or telomere damage (d’Adda di Fagagna
et al, 2003; Takai et al, 2003). Co-labeling of telomere ends
(telomeric fluorescence in situ hybridisation probes) and gH2AX
(immunohistochemistry) suggests that, at least some of, the
gH2AX expression is related to telomere damage in these tumours
(Figure 1).
For a subgroup of 26 patients, which did not differ in terms of
clinical features from the overall group, frozen tissue was available
for telomere length analysis. In contrast to our study of low-grade
astrocytomas, which were telomerase negative and had long
telomeres, ependymomas showed a marked variability in telomere
length (mean 6.5kb, range 3.6–9.1kb) (Figure 2). We did not
detect the abnormal heterogeneous TRF signal that is found in
ALT (White et al, 2001) in this cohort. There was a strong
correlation between hTERT expression and enzymatic activity
(Pearson’s w
2 Po0.0001, Table 3). Interestingly, there was no
association between the absence of hTERT expression and shorter
telomeres (o6kb) (Pearson’s w
2 P¼0.56). Moreover, short
telomeres were not associated with evidence of DNA damage
(gH2AX expression) or with PFS (Table 3).
In contrast, there was an inverse correlation between gH2AX
(DNA/telomere damage) and hTERT expressions (Pearson’s w
2
P¼0.011). Of 67 hTERT(þ) tumours, 52 (78%) lacked gH2AX
expression as compared with 20 (54%) of 37 hTERT( ) tumours,
suggesting a protective effect of hTERT against increased DNA/
telomere damage. This was true regardless of telomere length,
indicating that hTERT could protect even short telomeres from
becoming dysfunctional. Conversely, in the absence of hTERT
expression, 100% (four out of four) of ependymomas with long
telomeres exhibited gH2AX and did not progress clinically.
These observations suggest that in the absence of telomerase,
DNA damage and tumour growth arrest can occur even before
significant telomere shortening.
Telomerase in recurrent tumours
To overcome the lack of cell lines or other preclinical models and
to assess aspects of telomere maintenance over time in vivo,w e
analysed patients who had had recurrent resections due to tumour
progression. Clinical data and hTERT status by resection number
are summarised in Table 1. Thirty-seven patients had at least 2
resections and 12 had at least 3 resections. Of 14 grade 2 tumours,
7 had changed to grade 3 at relapse. Of the seven patients who
progressed from grade 2 to grade 3, five were hTERT(þ) both at
initial presentation and recurrence and 2 were hTERT( ) at initial
Table 3 Correlation of pathological markers with telomere maintenance
factors and progression-free survival
Parameter
hTERT(+)
P-value (v
2)
cH2AX( )
P-value (v
2)
PFS univariate
P-value (log rank)
MIB1412% o0.0001 0.27 0.02
Tumour grade 3 0.001 0.002 0.018
Hypercellularity 0.075 0.03 0.31
Mitoses 45/10 HPFs 0.005 0.006 0.39
Loss of pseudorosettes 0.29 0.8 0.42
Foci of necrosis 0.8 0.3 0.87
Vascular proliferation 0.72 0.09 0.28
Nuclear atypia 0.74 0.31 0.6
gH2AX-negative 0.016 — 0.007
Telomere length o6.5 0.6 0.4 0.44
TRAP-positive o0.0001 0.6 0.04
Figure 1 Co-staining for telomeres and gH2AX. Representative nucleus
showing double labelling with the gH2AX antibody (green, left panel) and
telomeric FISH probe (red, middle panel). The merged view (right panel)
shows yellow dots demonstrating DNA damage (gH2AX positivity) at the
telomeres.
15 14 13 12 M 11 10 9 8 7 6 5 4 3 2 1 M
21
8.6
3.5
10 9 8 7 6 5 4 3 2 1
Figure 2 Telomere length and telomerase activity in our cohort.
(A) Telomerase activity (TRAP assay; lane 1: buffer, lane 2: HeLa control,
lane 3: heat-inactivated control, lanes 4–10: tumour samples.) (B) Telo-
mere length (TRF assay; M represents molecular marker, lanes 1–15:
tumour samples.) was assessed in 26 samples. There was high correlation
between telomerase activity and hTERT expression (Po0.0001). We did
not find evidence of alternative lengthening of telomeres in this cohort.
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spresentation and hTERT(þ) at recurrence. None of 23 grade 3
tumours regressed to grade 2. Of the grade 3 ependymomas,
six were hTERT( ) at initial presentation and two of these became
hTERT(þ) with recurrence. Five of 10 hTERT( ) tumours
recurred as hTERT(þ). Only 1 of 22 hTERT(þ) tumours recurred
as hTERT( ). However, this tumour recurred again and became
hTERT(þ), indicating a likely sampling artefact at the second
resection.
Taken together, these findings support the concept that tumours
tend to evolve towards a more aggressive biological phenotype
at relapse. However, interestingly tumours that continued to lack
hTERT expression had a better OS even at recurrence (log rank
P¼0.05). The mean OS was 8.6±2.2 years in the patients who
were hTERT( ) at relapse as compared with 1.8±0.37 years in the
patients who were hTERT(þ) at relapse. None of the other factors
(MIB-1, number of mitoses, nuclear pleomorphism, necrosis,
hypercellularity or vascular proliferation) were predictive of
outcome at recurrence or showed significant differences between
consecutive samples. To our knowledge, hTERT is the first
described prognostic factor for recurrent ependymomas (Figure 2).
Effect of radiation and chemotherapy on telomere
maintenance
To assess resistance to prior therapy, we analysed gH2AX as a
marker of DNA damage in recurrent tumours from patients who
had undergone radiation and/or chemotherapy between their first
and second resections. The average duration between radiation
and re-resection was 3.1 years (s.d.: 1.7), thus short-term effects
of radiation could not be assessed. Of 18 irradiated tumours,
15 (83%) were negative for gH2AX. Non-irradiated tumours had
the same rate of gH2AX negativity (84%) regardless of time from
therapy. Tumours from 10 of 13 (77%) patients treated with
chemotherapy exhibited the same pattern of negative gH2AX at the
next resection, indicating a lack of prolonged DNA damage
response to chemotherapy in recurrent ependymomas. Only one of
15 (7%) and none of 17 (0%) tumours exhibited reduction in
hTERT expression after radiotherapy and chemotherapy, respec-
tively, suggesting no long-term effects of treatment on hTERT
status.
Combining telomerase expression and tumour DNA/
telomere damage stratifies patients into three prognostic
groups
Previously, we reported that hTERT expression predicts survival in
paediatric ependymoma at first resection (Tabori et al, 2006a). To
determine whether proliferative markers that correlate with
hTERT expression could predict outcome, we analysed each
marker separately. Of the proliferation and differentiation markers
tested (Table 3), only MIB-1 was associated with improved PFS at
first surgery. Using the median as a cutoff between high (412%)
and low (p12%) MIB-1 proliferative index, we found that
MIB-1412% was predictive of a reduced PFS (P¼0.021) and
approached significance in predicting a poorer OS (P¼0.084) for
patients at their initial surgical resection. MIB-1 failed to predict
PFS in recurrent tumours (P¼0.1) and was not inde-
pendent of hTERT status in predicting outcome in multivariate
analysis.
We next examined whether gH2AX expression (i.e., DNA/
telomere damage) influenced survival in the current cohort. At
first surgical resection, gH2AX expression was predictive of a
better PFS (log rank, P¼0.007) and better OS (log rank, P¼0.027)
(Table 4). Progression-free survival was 45 and 19% in 115
tumours expressing and lacking gH2AX, respectively (P¼0.007).
gH2AX was not independent of hTERT in predicting survival on
multivariate analysis (Table 4), but by combining gH2AX and
hTERT expressions, we could stratify patients into three statis-
tically significant groups (Figure 4). Patients with tumours who
lacked telomerase and showed dysfunctional telomeres (hTERT( )
/gH2AX(þ)) had 5-year PFS and OS of 69þ15% and 100%,
respectively; whereas patients with tumours who maintained their
telomeres (hTERT(þ)/gH2AX( )) had 5-year PFS and OS of
17þ8% and 22þ9%, respectively (Po0.0001). After 8 years, only
5% of the latter group had survived (Figure 4). Patients with
hTERT(þ)/gH2AX(þ) and hTERT( )/gH2AX( ) tumours exhi-
bited intermediate outcomes.
DISCUSSION
Ependymomas are glial tumours with erratic clinical behaviour.
Some tumours behave like low-grade gliomas with prolonged
remissions, whereas others progress relentlessly in a manner
similar to high-grade gliomas. The biological relevance of telomere
maintenance in paediatric ependymomas has, until recently, been
poorly understood. While exploring improved prognostication and
the identification of potential targets for new therapies, we recently
reported that hTERT (the catalytic subunit of telomerase)
expression is an excellent predictor of survival in newly diagnosed
paediatric ependymomas (Tabori et al, 2006a). hTERT expression
was found in 58% of ependymomas and conferred a worse
prognosis. This finding led to a number of relevant questions
concerning the role of telomere biology in paediatric ependy-
moma, some of which are addressed in this study.
Telomere maintenance is one of the hallmarks of cancer and this
is believed to allow their continued proliferation (Hanahan and
Weinberg, 2000). Another function of telomerase is to prevent
DNA ends being recognised as DNA breaks, which would be
catastrophic to normal cells. Thus, we hypothesised that
hTERT(þ) tumours would show more proliferative potential, less
DNA damage and longer telomeres. Our data support a role for
telomerase in ependymomas in allowing proliferation as hTERT
expression correlated with both increased mitotic index and MIB-1
proliferative index in our ependymoma cohort (Table 3). This is
important as a variety of studies (De Semir et al, 2007; Jackson
et al, 2007) have suggested other roles for telomerase in
proliferating cells.
Table 4 Multivariate analyses of clinical and biological markers
Parameter
PFS univariate P-value
(log rank)
PFS multivariate
P-value (Wald)
OS univariate P-value
(log rank)
OS multivariate
P-value (Wald)
Extent of resection 0.011 0.021 0.091 0.337
Age (years) 0.012 0.028 0.021 0.22
Metastatic disease 0.02 0.886 0.066 0.372
WHO grade 0.018 0.128 0.016 0.301
gH2AX 0.007 0.133 0.027 0.247
hTERT 0.001 0.075 o0.0001 0.002
MIB1 0.021 0.122 0.084 0.472
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protecting cells from DNA damage by demonstrating an inverse
correlation between hTERT and gH2AX expressions (Table 3).
However, in contrast to our hypothesis, we found no correlation
between telomere length and hTERT expression or evidence of
DNA damage. This observation suggests the importance of
telomerase in protecting telomeres even at very short lengths.
However, telomere homoeostasis is regulated by multiple and
complex protein interactions, including the proteins of the
shelterin complex, thus other proteins may also have a function.
There was no correlation between hTERT or gH2AX status and
prior chemotherapy or radiotherapy, suggesting no long-term
effects of treatment on the expression of these proteins. This is also
in keeping with an intact p53 pathway in ependymomas as has
been suggested by several other studies (Fink et al, 1996; Gaspar
et al, 2006).
Within the glial neoplasms, low-grade gliomas lack telomerase
activity and ALT, and thus fail to maintain their telomeres (Chong
et al, 1998; Tabori et al, 2006b). This results in progressive
telomere attrition and may be associated with the unique tendency
of paediatric low-grade gliomas to undergo growth arrest (Tabori
et al, 2006b) and their associated excellent survival. On the
other hand, telomerase is actively expressed in most high-grade
astrocytomas and embryonal brain tumours (Falchetti et al, 2002;
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Figure 4 hTERT and gH2AX expressions as prognostic markers in paediatric ependymomas. The addition of gH2AX expression is able to further subdivide
patients into prognostic groups. Group A: hTERT(þ)/gH2AX( ); Group B: hTERT(þ)/gH2AX(þ); Group C: hTERT( )/gH2AX( ); and Group D:
hTERT( )/gH2AX(þ)( A). Note that patients with hTERT( )a n dgH2AX(þ) tumours are all alive while there is only 22% 5-year survival for those with
hTERT(þ), gH2AX( ) tumours. **Po0.001 (Group A vs Group D). (B) The Kaplan–Meier analysis showing that those patients with gH2AX(þ)t u m o u r s
faired better even when hTERT continued to be expressed. OS, overall survival; PFS, progression-free survival. Values represent mean±s.e. of the mean.
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Figure 3 hTERT expression predicts survival in recurrent ependymoma.
Overall survival was assessed for ependymomas at first recurrence (n¼30).
There were no long-term survivors in the hTERT(þ) tumours (P¼0.05).
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sHakin-Smith et al, 2003), which may contribute to their worse
outcome. Telomere maintenance also seems to have a function in
prognosis in adult high-grade gliomas, in which 15% of tumours
display ALT and this confers a better prognosis (Hakin-Smith et al,
2003). We examined this in our current study and found
no evidence of ALT in any of the 26 samples available to be
tested. This suggests that ependymomas rely predominantly on
telomerase activity to maintain their telomeres and may explain
our findings regarding telomere length.
The biological importance of our findings is supported by the
prognostic significance conferred by the demonstration of telo-
mere maintenance (hTERT expression) and lack of telomere dys-
function (gH2AX negativity) in paediatric ependymomas (Figures
3 and 4). The striking difference in PFS between morphologically
similar tumours, which lack hTERT expression and show telomere
dysfunction (gH2AX positivity) on the one hand, and tumours that
express hTERT and have functional telomeres (gH2AX( )) on
the other, may allow for a reevaluation of tailored management
for these patients. Development of a biologically rational therapy
is especially important because most of these patients are young
children for whom exposure of the developing brain to conven-
tional high-dose radiation and chemotherapy often leads to
devastating short- and long-term neurocognitive sequelae. A
possible model may include reduction or delaying chemoradiation
for patients in Group D (Figure 4), whereas introducing telomerase
inhibitors to Group A patients.
It is also important to note that the ability to assess tumour
progression in vivo over a period of several years and following
different treatment regimens offers an opportunity for a more
accurate view of the real biological mechanisms that govern
tumour progression. This is particularly relevant as ependymomas
lack relevant preclinical models and given the recent challenges to
the reliability of cell lines to mimic in vivo tumour behaviour
(Lee et al, 2006).
In summary, this study adds new dimensions to our under-
standing and utilisation of telomere biology for prognostic and
predictive purposes in paediatric ependymomas. Our results are
particularly timely, as telomerase inhibitors are currently under
evaluation in adult phase I clinical trials, and they may thus
offer an attractive option for the management of children with
ependymomas as well.
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